Abstract
Abstract
Purpose of Review
Both chimeric antigen receptor (CAR) T cells and T cell–engaging antibodies (BiAb) have been approved for the treatment of hematological malignancies. However, despite targeting the same antigen, they represent very different classes of therapeutics, each with its distinct advantages and drawbacks. In this review, we compare BiAb and CAR T cells with regard to their mechanism of action, manufacturing, and clinical application. In addition, we present novel strategies to overcome limitations of either approach and to combine the best of both worlds.
Recent Findings
By now there are multiple approaches combining the advantages of BiAb and CAR T cells. A major area of research is the application of both formats for solid tumor entities. This includes improving the infiltration of T cells into the tumor, counteracting immunosuppression in the tumor microenvironment, targeting antigen heterogeneity, and limiting off-tumor on-target effects.
Summary
BiAb come with the major advantage of being an off-the-shelf product and are more controllable because of their half-life. They have also been reported to induce less frequent and less severe adverse events. CAR T cells in turn demonstrate superior response rates, have the potential for long-term persistence, and can be additionally genetically modified to overcome some of their limitations, e.g., to make them more controllable.
Funder
H2020 Marie Skłodowska-Curie Actions
Hector Fellow Academy
Melanoma Research Alliance
Else Kröner-Fresenius-Stiftung
Deutsche Krebshilfe
Jung-Stiftung für Wissenschaft und Forschung
Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft
José Carreras Foundation
International Doctoral Program i Target: Immunotargeting of Cancer funded by the Elite Network of Bavaria
LMU Munich’s Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
European Research Council
Marie-Sklodowska-Curie Program Training Network for the Optimizing adoptive T cell therapy funded by the H2020 Program of the European Union
Deutsche Forschungsgemeinschaft (DE) within Sonderforschungsbereich SFB 1243
Wilhelm-Sander Stiftung
Amgen
Miltenyi Biotec
Gilead
Morphosys
Roche
Seattle Genetics
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献